Equillium Inc (EQ) Stock Forecast & Price Target

Equillium is compelling because its lead asset EQ504 targets the biologically validated AhR pathway in ulcerative colitis with a colon-specific, oral design that aims to maximize local efficacy while minimizing systemic exposure and safety risk. The thesis is strengthened by robust preclinical evidence across 14 models, including dose-dependent CYP1A1 induction, IL-10/IL-22 upregulation, preserved barrier function, and reduced inflammatory pathology, plus human intestinal tissue data showing translational target engagement. In addition, the company has a second asset, EQ302, whose celiac-disease optionality is increasingly credible after controlled IL-15 blockade data in the market, while Equillium’s $61.3M cash position and funding into 2029 reduce near-term financing pressure.

Equillium is viewed negatively because its lead asset EQ504 remains preclinical in humans, while Phase 1 timing has already slipped to 4Q26 and any further delay would push biomarker data beyond 2Q27E and first efficacy data to 2H28E. The case depends on unproven biomarker-to-efficacy translation from CYP1A1, IL-10, and IL-22, yet safety, regulatory, and competitive risks are substantial, including possible PAH signals, Azora’s AT-177, and obefazimod’s planned late-2026 NDA. Financially, the company’s $57.2M cash at June 30 or $61.3M at March 31, 2026 may fund operations into 2029, but a negative Phase 1 could force a dilutive raise and imply only about $0.34 to $0.35 per share on residual cash.